Treating chronic diseases with cells that possess stem-like properties is thoroughly investigated. PDAC® cells are Placenta-derived activated cells that have been shown to have tissue repair, anti-inflammatory and pro-angiogenic properties. These unique traits make them a pertinent source of cells as potential treatment for vascular diseases such as hindlimb ischemia.
Angiogenic properties of human placenta-derived adherent cells and efficacy in hindlimb ischemia. – PubMed – NCBI
J Vasc Surg. 2016 Sep;64(3):746-756.e1. doi: 10.1016/j.jvs.2015.04.387. Epub 2015 Jun 6.
These cells are also the object of an ongoing cell therapy clinical trial to evaluate their safety and effectiveness to treat patients with Peripheral Arterial Disease and Diabetic Foot Ulcer.
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU – Full Text View – ClinicalTrials.gov
This clinical study is being conducted to assess the safety and determine the maximum tolerated dose (MTD) of PDA-002 [human placenta-derived cells] administered into the lower leg muscles of subjects with peripheral arterial disease and diabetic foot ulcers. It will look to see if PDA-002 helps reduce some of the symptoms of PAD and/or improves ulcer healing.
Pharmaseed as a strong R&D experience for vascular diseases and has developed an extensive angiogenesis program. Our Hind Limb study package includes:
– Evaluation of the efficacy of a test item on angiogenesis
– Functional outcome in mice and rodents
for more details, please see below or contact us: email@example.com
Pharmaseed has extensive vascular-related diseases know-how. We have developed a comprehensive Hind Limb Ischemia pre-clinical program: – Evaluation of the efficacy of a test item on angiogenesis – Functional outcome in mice and rodents For more information: contact us